Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$29.24 USD

29.24
739,206

+0.90 (3.18%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $29.22 -0.02 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 46% (136 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed

Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.

    Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now

    Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

      Here's Why Investors Should Buy Integra LifeSciences Now

      The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.

        3 Plastic & Reconstructive Surgery Stocks Looking Good

        Consider these three stocks for raking in grand returns from the fast-growing plastic and reconstructive surgery market.

          Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm

          Integra (IART) widens its tissue technology segment with the launch of Revize/Revize-X Collagen Matrix for plastic and reconstructive surgery.

            Integra Rides High on Product Launches, Competition Rife

            Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.

              Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line

              Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.

                Integra Closes Codman Buyout, Strengthens Neurosurgery Arm

                With Codman's acquisition by Integra (IART), the neurosurgery business is likely to drive the company's 2018 adjusted earnings per share with a minimum yield of 22 cents.

                  Integra Divests Assets to Natus, Paves Way for Codman Buyout

                  Integra LifeSciences' (IART) divestment of certain neurosurgery assets to Natus Medical is part of the company's agenda to meet closing conditions toward the Codman neurosurgery business buyout.

                    Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss

                    Integra LifeSciences' (IART) solid performance in the Orthopedics and Tissue Technologies was the key highlight of the second quarter.

                      Integra LifeSciences (IART) Up 8.5% Since Earnings Report: Can It Continue?

                      Integra LifeSciences (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        Integra LifeSciences to Offer aap's LOQTEQ System in the US

                        Global medical technology major, Integra LifeSciences Holdings Corporation (IART) recently inked an agreement with aap Implantate AG, a Berlin-based trauma product maker.

                          Integra Lifesciences Hits 52-Week High on Product Launches

                          Share price of Plainsboro NJ-based Integra Lifesciences Corporation (IART) reached a new 52-week high of $47.50 on May 19, finally closing a tad lower at $47.39.

                            Integra LifeSciences (IART) Misses Q1 Earnings, Retains View

                            Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 39 cents in the first quarter of 2017, which marked a 2.6% increase from the year-ago number.

                              Integra LifeSciences (IART) Q1 Earnings: A Beat in Store?

                              We expect Integra LifeSciences Holdings Corporation (IART) to beat expectations when it reports its first-quarter 2017 results, after market close on Apr 26.

                                Integra LifeSciences Expands Cadence System Commercially

                                Integra LifeSciences Holdings Corporation (IART), a global medical technology company, recently announced full commercial expansion of its Cadence Total Ankle System.

                                  Integra (IART) Titan Reverse Launch Expands Extremity Line

                                  Integra LifeSciences (IART) recently broadened its extremity product line with the launch of its Titan Press-Fit Reverse Shoulder for Fracture.

                                    Integra (IART) Posts In-Line Q4 Earnings, Issues 2017 View

                                    Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 52 cents in the fourth quarter of 2016, up 18% from the year-ago adjusted number.

                                      Integra LifeSciences at 52-Week High on Deals, View Update

                                      Shares of Integra LifeSciences Holdings Corporation (IART), a global leader in medical technology, scaled a new 52-week high of $45.50 on Jan 10, closing a tad lower at $44.90.

                                        Kevin Matras headshot

                                        Why the P/S Ratio is My Favorite Valuation Metric

                                        This week, Kevin Matras shows how to use the Price to Sales ratio. Highlighted stocks include BECN, CORE, HNI, IART and POST.